Intensity Therapeutics, Inc.
8 Wright Street
Suite 107
Westport
Connecticut
06880
United States
Tel: 203-682-2434
Fax: 203-664-1051
About Intensity Therapeutics, Inc.
Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lewis H. Bender
Chief Medical Officer: Ian B. Walters, MD
78 articles about Intensity Therapeutics, Inc.
-
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
4/2/2024
Intensity Therapeutics, Inc. (Nasdaq: INTS) announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024.
-
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
3/14/2024
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS) announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.
-
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
3/14/2024
Intensity Therapeutics, Inc. announces that Lewis H. Bender , Founder, President will participate in a fireside chat with Roth Managing Director and Senior Analyst, Jonathan Aschoff, Ph.D. at the 36th Annual Roth Conference in Orange County, CA on Tuesday, March 19, at 12:30PM PDT.
-
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
2/21/2024
Intensity Therapeutics, Inc. today announced that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the 2024 BIO CEO & Investor Conference on Monday, February 26, 2024, at the New York Marriott Marquis at 11:45am ET in the Uris Room.
-
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
1/3/2024
Intensity Therapeutics, Inc. today announced a business update reflecting progress in its phase 3 sarcoma clinical program.
-
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
12/12/2023
Intensity Therapeutics, Inc. today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO).
-
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
12/8/2023
Intensity Therapeutics, Inc. today announced that safety, tolerability, efficacy and immune activation data from the company's Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.
-
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
12/1/2023
Intensity Therapeutics, Inc. today announced that it has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.
-
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
11/13/2023
Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage biotechnology company that applies novel engineered chemistry to discover and develop proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
11/2/2023
Intensity Therapeutics, Inc. announced that safety, tolerability and efficacy data from IT-01, the company's ongoing Phase 1/2 clinical trial of INT230-6, either as a monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, was presented at the Connective Tissue Oncology Society 2023 Annual Meeting being held in Dublin, Ireland from November 1-4, 2023.
-
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
9/7/2023
Intensity Therapeutics, Inc. today announced that the US Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (STS) to the three active moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl) amino)octanoate).
-
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Intensity Therapeutics, Inc. (Nasdaq: INTS) today announced that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, at 4:30 pm ET.
-
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
8/14/2023
Intensity Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
-
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
8/7/2023
Intensity Therapeutics, Inc. today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets. A conference call and webcast will follow at 8:00 am ET.
-
7 Life Science IPOs in 2023
7/12/2023
A handful of biotechs and pharma companies have posted sizable IPOs in 2023, despite a tight economy. Still, the numbers are way down from last year. -
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
7/10/2023
Intensity Therapeutics, Inc. today announced that the underwriters of its previously announced initial public offering have fully exercised their option to purchase an additional 585,000 shares of its common public stock at the IPO offering price of $5.00 per share, less underwriting discounts and commissions.
-
Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
7/5/2023
Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS) today announced the closing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.
-
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
6/30/2023
Intensity Therapeutics, Inc. announced the pricing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.
-
Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
6/6/2023
Intensity Therapeutics, Inc. today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.
-
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas - June 03, 2023
6/3/2023
Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 2-6, 2023.